Water Tower Research (WTR) Adds Do Kim as Senior Research Analyst

May 1, 2024, St. Petersburg, FL—Water Tower Research LLC (www.watertowerresearch.com) is modernizing IR with a powerfully differentiated ecosystem of investor relations services, research-driven content and communications, and investor engagement. Water Tower Research is pleased to announce that Do Kim will join the firm as Senior Research Analyst.

Shawn Severson, CEO and Co-Founder, said, “We are pleased to announce the addition of Do to the WTR team.  The biotech and healthcare sectors are rapidly growing verticals for WTR and Do brings a wealth of experience and expertise to expand our efforts. Our foundation begins with the high caliber of our analysts, and we are looking forward to Do’s contributions as we expand our presence in this key market.”

Also commenting on Mr. Kim, Joy Malone, President and Chief Operating Officer, said, “We see a significant opportunity in the healthcare sector where we can add substantial value in helping investors and companies connect through our research-driven platform and IR ecosystem. Having Do on board is a great addition to the team and our effort here. We are excited to have him on board as we continue to build out this key vertical.”

Do has more than 20 years of equity research experience in the biotechnology space, covering large- to smid-cap companies, as well as a broad range of therapeutic areas and drug development platforms. His areas of expertise include oncology, cell therapy, autoimmune, rare diseases, inflammatory, infectious diseases, antibody technology, AI/ML-enabled drug discovery, vaccines, cell therapy, RNAi, mRNA, gene therapy, and small molecules.

Previously, Do was a senior sell-side analyst at Piper Sandler, BMO Capital Markets, and Nomura Securities, with prior coverage of the largest biotech names and multiple companies from the start of their initial public offerings. He also spent time as a buy-side analyst at Safra Asset Management, responsible for value investments in the healthcare industry.

Before Wall Street, Do conducted genetic and molecular cell biology research at the Kennedy Krieger Institute, the pediatric affiliate of Johns Hopkins Hospital, where he co-authored 17 peer-reviewed articles in scientific journals, including Nature Genetics. Do graduated with a BA degree in Biology from the Johns Hopkins University and an MBA in Finance and Economics from Columbia Business School. Do is also a CFA charterholder.

About Water Tower Research 

Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.

Tags: biotech, Diseases, drug development, Healthcare, Oncology, therapeutics